This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Industry Updates
  • Companies
  • Glaukos
Web: https://www.glaukos.com
Email: nsmith@glaukos.com

Glaukos


GLAUKOS - TRANSFORMING GLAUCOMA THERAPY

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialisation of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

The ethos of their current product offering is the need to intervene early in treating glaucoma, one of the world’s leading cause of blindness.  With an ultimate goal of slowing down the progression of the disease and delaying the need for more invasive treatments.

In 2001, Glaukos pioneered micro-invasive glaucoma surgery or MIGS in order to revolutionise the traditional glaucoma treatment and management paradigm.  MIGS, specifically trabecular micro-bypass surgery, is now a widely accepted approach in attempting to lower intraocular pressure in mild-to-moderate open-angle glaucoma.  Trabecular micro-bypass surgery can help reduce the need for more aggressive surgical options.

Glaukos launched the iStent®, the first device designed for trabecular micro-bypass surgery, in the United States in 2012.  iStent inject ® is the smallest medical device known to be approved by the Food and Drug Administration, or FDA, measuring 0.36 mm long and 0.23 mm wide. More than 500,000 stents have been sold since 2012.

Glaukos’s aim is to leverage the iStent® platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies that advance the existing glaucoma standard of care and enrich the lives and treatment alternatives for glaucoma patients worldwide.

Videos - iStent Inject

12 June 2019 | Research & Development

Trabecular bypass surgery with iStent Inject enhances aqueous outflow from the eye , evidence of this is demonstrated through Angiographic visualization of aqueous humor outflow in studies conducted by Dr. Alex Huang M.D, Ph.D

Navigation
  • Companies
  • News updates
Company Specialties
  • Awards & Conferences
  • Personnel
  • Research & Development

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency